Abstracts

654 – Lipoprotein(a) Trajectories in Aging PLWH on Long-Term Suppressive ART: A 7-Year Follow-Up Study

Background Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein associated with atherosclerotic cardiovascular disease (ASCVD). Current guidelines recommend a once-in-a-lifetime measurement, assuming stability over time. However, chronic inflammation in people living with HIV (PLWH) may influence Lp(a) trajectories. Data on long-term Lp(a) stability in aging PLWH on suppressive ART remain limited. Methods We analyzed participants from…

1113 – A Roadmap to New Models for Long-Acting Injectable Antiretroviral Administration

Background Long-acting cabotegravir and rilpivirine (LA CAB/RPV) is injected intramuscularly typically by a nurse in clinic. As more people with HIV (PWH) are switching to long-acting injectable (LAI) antiretroviral therapy (ART), expanding access through different models of care is needed. Perspectives from PWH on in clinic administration of LA CAB/RPV could provide critical insight to…

663 – Association of Trimethylamine N-Oxide and Cardiovascular Disease in People With and Without HIV

Background Understanding how HIV contributes to excess cardiovascular disease (CVD) risk beyond traditional CVD risk factors is important to identify interventions to reduce CVD risk for people with HIV (PWH). Microbiome dependent metabolites may represent novel modifiable biomarkers of CVD risk PWH. Alterations in gut microbial composition may affect the production of microbiome dependent metabolites like…

1115 – HIV PrEP Use and Interest Among People Hospitalized With Infections due to Injecting Drugs

Background People who inject drugs (PWID) are at risk for HIV infection due to sexual practices and shared injection equipment, but face barriers to accessing pre-exposure prophylaxis (PrEP). Hospitalization for injection drug use (IDU)-related infections may be an opportunity to reduce risk of HIV infection, but data on PrEP interest and preferences in PWID hospitalized…

947 – Depressive Symptoms in 2 Prospective HIV Cohorts in Latin America: A Comparative Analysis by Sex

Background Depression is common among people living with HIV (PWH), disproportionately affecting women.  Despite its impact on adherence, disease progression, and mortality, depression is underrecognized in HIV care in Latin America. We evaluated sex differences in the prevalence and 12-month trajectory of depressive symptoms (DS) in two prospective cohorts within the Caribbean, Central, and South…

962 – Using HIV Antibody Avidity to Monitor Long-Term Antiretroviral Therapy: A Proof-of-Concept Study

Background Lifelong antiretroviral therapy (ART) is the mainstay of HIV care, but can be challenging to maintain. HIV viral load (VL) testing is the standard for monitoring ART, but requires laboratory infrastructure and only reflects recent ART. Long-term ART has been hypothesized to reduce HIV antibody avidity, which can be measured by rapid immunoassays, potentially…

715 – AI-Supported Strategies to Optimize Polypharmacy and Medication Safety in Aging People With HIV

Background In people with HIV (PWH), multimorbidity often leads to polypharmacy, which increases the risk of adverse drug reactions, drug–drug interactions (DDIs), poor adherence, and functional decline, underscoring the need for safer prescribing strategies. We describe the implementation of a multidisciplinary, AI-supported quality improvement (QI) intervention at the Modena HIV Metabolic Clinic (MHMC) to optimize…

798 – Improved Retention After Implementing Differentiated Services for Postpartum Women With HIV in Kenya

Background Differentiated service delivery (DSD) streamlines HIV care for people on antiretroviral therapy (ART) by extending clinic visit intervals and refill durations. HIV treatment guidelines in sub-Saharan Africa, including Kenya, now expand DSD eligibility to include postpartum women with HIV (PPWH). We evaluated DSD implementation and retention in care for PPWH within a large HIV…

1003 – Weight Change After CAB-LA Initiation Among PrEP-Naive Users and Daily TDF/FTC Switchers

Background Weight gain has been reported with integrase inhibitors in HIV treatment, raising concerns for long-acting cabotegravir (CAB-LA) used in HIV prevention. In treatment settings, removal of TDF has also been linked to weight increases, suggesting that switching from daily oral PrEP with TDF/FTC to CAB-LA could alter weight trajectories.  Methods We analyzed a prospective…